Vizamyl (flutemetamol f 18) is a small molecule pharmaceutical. Flutemetamol f 18 was first approved as Vizamyl on 2013-10-25. It has been approved in Europe to treat alzheimer disease and radionuclide imaging. The pharmaceutical is active against amyloid-beta precursor protein. Vizamyl's patents are valid until 2028-09-16 (FDA).
|Common Name||Flutemetamol (18f)|
|Indication||alzheimer disease, radionuclide imaging|